Melanoma vaccines.
Melanoma vaccines are the best near term hope for improving mortality in patients with advanced disease. Although these vaccines are being developed for treatment of patients with advanced disease, their relatively low toxicity make them attractive for adjuvant therapy in stage I patients at high risk for recurrence. Recent developments in melanoma vaccines are reviewed and their importance to dermatologists is emphasized.
Naylor
M F
MF
Department of Dermatology, University of Oklahoma Health Sciences Center, USA.
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006801:Humans; D007155:Immunologic Factors; D007378:Interleukins; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D011971:Receptors, Immunologic; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated; D022223:Vaccines, Subunit
D019496:Cancer Vaccines; D007155:Immunologic Factors; D007378:Interleukins; D011971:Receptors, Immunologic; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated; D022223:Vaccines, Subunit; D016178:Granulocyte-Macrophage Colony-Stimulating Factor